Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples